This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
NFATC1 · Western blot design guide
NFATC1 Western Blot Planning Guide
Plan a NFATC1 Western blot around the catalog-observed 101.2 kDa band, image-backed A00340-2 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
NFATC1 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 101.2 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 8-10% | |
| Positive control | Appendix | |
| Negative control | Bronchus |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 101.2 kDa |
| ⓘ | Localization | Cytoplasm / Nucleus |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated NFATC1 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Appendix |
| Gel % | 8-10% |
| Load | 20-30 µg total protein per lane |
| Transfer | Wet/tank, extended transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A00340-2 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected NFATC1 Western Blot Band Size?
Use the product-observed 101.2 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 101.2 kDa | Matches the authoritative product WB observation. |
| 101.2 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected NFATC1 appearancePlan around 101.2 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 101.2 kDa; use this as the primary experimental expectation. |
| Calculated mass | 101.2 kDa from UniProt O95644; retain as context. |
| Gel selection | 8-10%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A00340-2. |
| Situation | Likely cause | Next action |
|---|---|---|
| 101.2 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing NFATC1 band
A00340-2 · NFATC1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for NFATC1 Western blot
🧪Use Appendix as the first positive-control candidate and Bronchus as the HPA Not detected negative candidate.
Positive control: Appendix (High)
Negative control: Bronchus (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for NFATC1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Reported tissue cells | High | Protein (HPA) | HPA → |
| Lymph node | Reported tissue cells | High | Protein (HPA) | HPA → |
| Tonsil | Reported tissue cells | High | Protein (HPA) | HPA → |
| Bone marrow | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced NFATC1 Western Blot Tips
Deeper troubleshooting and optimisation questions for NFATC1, answered from its protein features.
Which band should guide the blot?
Use 101.2 kDa, the observation attached to the authoritative A00340-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 101.2 kDa expectation.
Which positive control should I start with?
Start with Appendix, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Bronchus as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for NFATC1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A00340-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
NFATC1 Western Blot Reagents
Human/Mouse/Rat-reactive NFATC1 Western blot reagents with authoritative product imagery.
Real WB data
Anti-NFAT2/NFATC1 Antibody Picoband®
Cat # A00340-2
Real WB data
Anti-NFAT2/NFATC1 Antibody Picoband®
Cat # A00340-1
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt O95644
- Human Protein Atlas — NFATC1
- A00340-2 product record
- PMC8400789 — Delivery of the VIVIT Peptide to Human Glioma Cells to Interfere with Calcineurin-NFAT Signaling (Molecules (Basel, Switzerland), 2021)
- PMC12596296 — USP5 Deletion Inhibits KD Serum Induced-Human Coronary Artery Endothelial Cell Dysfunction by Regulating the NFATC1/TLR4-Mediated NF-κB Signaling Pathway in Kawasaki Disease (Inflammation, 2025)
- PMC3898803 — Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate (International journal of oncology, 2014)